12:00 AM
 | 
Oct 14, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

CPI-613 regulatory update

Cornerstone said FDA granted Orphan Drug designation to CPI-613 to treat myelodysplastic syndrome (MDS). Last month, the company began a Phase II trial of...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >